Peptide Therapeutics — Full Reference

Almost every dispute about peptides is a tier confusion. A mechanism shown in a cell line gets quoted as though it were a clinical outcome. Assign a tier before you assign belief.

Two structural warnings that apply across this whole field:

• Single-group corpora. A large share of BPC-157 literature comes from one research group in Zagreb, and a large share of the bioregulator literature from one group in St Petersburg. Independent replication is what converts a finding from "a group believes this" to "this is known." For both, independent replication is thin.
• Rodent-to-human is not a scaling problem, it is a translation problem. Allometric dose conversion tells you nothing about whether the effect exists in humans at all. Most drugs that work in rodents fail in humans.

A peptide is a chain of amino acids linked by peptide bonds. The conventional cut-off is roughly 2 to 50 residues; longer chains are called proteins. Peptides sit between small molecules and biologics: too large to reliably cross membranes or survive the gut, small enough to be chemically synthesised rather than grown in cells.

Three consequences follow, and they explain most of the practical constraints:

1. They are digested. Oral peptides are broken into amino acids by gastric and pancreatic proteases. Getting one orally active requires either heavy modification, a permeation enhancer, or both. Oral semaglutide (Rybelsus) uses the absorption enhancer SNAC and still delivers roughly 1% bioavailability.
2. They are cleared fast. Native peptides have plasma half-lives measured in minutes. Every long-acting peptide drug achieves it through engineering: fatty-acid acylation for albumin binding (semaglutide), a maleimide that covalently binds albumin (CJC-1295 with DAC), D-amino acid substitution, or PEGylation.
3. They are immunogenic in principle. Anti-drug antibodies are a real phenomenon for peptide therapeutics and are assessed in registration trials. They are not assessed at all for grey-market compounds.

Category errors to stop repeating. The source excerpt and its sales page list several things as peptides that are not peptides:

This matters beyond pedantry. A buyer who believes NAD+ is a peptide will apply peptide handling, peptide sourcing logic, and peptide risk assumptions to a molecule that shares none of them.

The excerpt's chronology contains several errors. Here is the corrected version.

The hypothalamic releasing factors. Roger Guillemin and Andrew Schally independently isolated and characterised the hypothalamic releasing hormones across roughly 1969 to 1973, working from enormous quantities of animal hypothalami. Thyrotropin-releasing hormone (TRH, 3 residues) was characterised in 1969. Gonadotropin-releasing hormone (GnRH, 10 residues) followed in 1971. Somatostatin (14 residues) was isolated by Guillemin's group in 1973.

They shared the 1977 Nobel Prize in Physiology or Medicine with Rosalyn Yalow, who was recognised separately for developing radioimmunoassay. The excerpt gives 1975 for the isolation and appears to conflate the two dates.

The "four neuropeptides of up to 14 amino acids" claim is not sustainable. Three of the classical hypothalamic peptides fit that description. The other two canonical members do not: corticotropin-releasing hormone (CRH), characterised by Wylie Vale's group in 1981, is 41 residues; growth hormone-releasing hormone (GHRH), characterised in 1982, is 44 residues.

Endogenous opioids. John Hughes and Hans Kosterlitz identified the enkephalins in 1975 and published in Nature. The excerpt has this right.

Candace Pert. Pert identified the opiate receptor with Solomon Snyder in 1973, as a graduate student, using radioligand binding. Her work extending neuropeptide receptor mapping into immune cells came later, through the 1980s. The 1985 paper often cited here is "Neuropeptides and their receptors: a psychosomatic network" in the Journal of Immunology. "Molecules of Emotion" is the title of her 1997 popular book, not a term coined in 1985.

BPC-157 does not belong in a 1980-1990 section. It is a synthetic 15-residue sequence derived from a fragment of a protein found in human gastric juice, developed by Predrag Sikirić and colleagues at the University of Zagreb. The published work begins in the early-to-mid 1990s, not the 1980s.

Mitochondrial-derived peptides. Humanin, a 24-residue peptide encoded in the mitochondrial 16S rRNA region, was reported in 2001 in the context of protection against amyloid-beta toxicity. MOTS-c, a 16-residue peptide encoded in the 12S rRNA region, was reported in 2015 in Cell Metabolism by Lee, Cohen and colleagues. The excerpt's 2015 date for MOTS-c is correct.

Dosing frequency is not a preference, a tradition, or a protocol design choice. It is arithmetic downstream of half-life. A compound with a 30-minute half-life administered once daily is present at meaningful concentration for well under an hour out of 24. Any protocol that ignores this is describing a ritual, not a pharmacological exposure.

The pulsatility point. Endogenous growth hormone is released in pulses, concentrated in early slow-wave sleep. The GH axis is regulated by that pulse pattern, and somatostatin tone between pulses is part of the signal. A short-acting GHRH analog produces a pulse. CJC-1295 with DAC does not — its six-to-eight-day albumin-bound half-life produces a continuous elevation, often called a "bleed." These are pharmacologically different interventions that the market sells under nearly the same name. Continuous stimulation of a G-protein-coupled receptor tends toward desensitisation and downregulation.

The feedback point. GHRH analogs and ghrelin-receptor agonists act on the pituitary, so the negative feedback loop through IGF-1 and somatostatin stays intact — there is a ceiling. Exogenous GH and exogenous IGF-1 bypass that loop and suppress endogenous production. The excerpt's claim that peptides "do not create dependence" is not true across the class; it is true for some mechanisms and false for others.

GHRH analogs

Tesamorelin is the important entry here. It is the proof that a GHRH analog can clear a full regulatory pathway, and its label is the best available guide to what this mechanism actually does to a human body over a year: visceral fat falls, IGF-1 rises, glucose tolerance worsens in a meaningful fraction of patients. That last item is routinely omitted from performance marketing.

Ghrelin receptor agonists (GHRPs and secretagogues)

GH and IGF-1

Fat-loss fragment

This is the only part of the field with T1 evidence at scale, and it is worth being precise about, because it is where the honest sales argument actually lives.

Class-wide adverse effects across GLP-1 and GIP/GLP-1 agonists: nausea, vomiting, diarrhoea, constipation; gallbladder disease and cholelithiasis; pancreatitis signal; gastroparesis and delayed gastric emptying, which has produced anaesthesia aspiration guidance from anaesthesiology societies; diabetic retinopathy progression signal seen with rapid HbA1c reduction; substantial loss of lean mass alongside fat mass; weight regain on discontinuation, demonstrated in the STEP 4 withdrawal design. The 2023 SELECT trial showed cardiovascular benefit with semaglutide in people with obesity and established cardiovascular disease without diabetes.

Investigational, not approved: retatrutide (triple GIP/GLP-1/glucagon agonist), survodutide, cagrilintide and the cagrilintide/semaglutide combination. These have T2 trial data but no approval as of this document's date. Verify current approval status before publishing.

The honest summary of this section: the regenerative peptides that dominate the marketing have the weakest evidence in the document, and the two compounds in this class that were tested most rigorously in humans — larazotide and elamipretide's myopathy trial — both missed their endpoints.

Immune

Neuro / cognitive

Melanocortin

Khavinson bioregulators

The bioregulator concept — that very short peptides act as regulatory signals on gene expression rather than as substrates — is a legitimate hypothesis with real mechanistic proposals behind it. What it does not have is the independent, multi-centre, long-horizon human evidence that the excerpt's framing implies. "This changed longevity medicine permanently" is not a supportable sentence.

The excerpt's central regulatory claim is that peptides cannot be patented and therefore cannot be developed. This is false, and it is load-bearing for the whole argument, so it is worth dismantling precisely.

The patent claim is wrong

The honest version of the argument is narrower and still worth making: for unmodified endogenous sequences with no viable exclusivity position, commercial sponsorship is genuinely absent, and so the evidence base stays thin indefinitely. That is true of BPC-157. It is not true of the field.

On trial costs: the excerpt's per-phase figures ($50M / $120M / $500M) are presented as fixed facts. The published estimates in this area, principally from the Tufts/DiMasi line of work and its critics, are capitalised cost per approved drug including failures and cost of capital, not out-of-pocket cost per phase, and the estimates vary by an order of magnitude between authors. Quote a range with a source or drop the numbers.

Status by jurisdiction

The "research use only" mechanism

Grey-market peptide supply operates by labelling product "for research use only, not for human consumption." That label is the entire legal architecture of the sector. It also means, mechanically, that the product is not manufactured, tested, released, or stored to pharmaceutical standard, and that no pharmacovigilance system exists behind it.

This is the single largest omission in the source material. The product is sold to "the modern athlete" and contains no mention of anti-doping status at all. An athlete in a tested sport who follows its base protocol fails a test.

The World Anti-Doping Agency Prohibited List is revised annually and takes effect on 1 January. Categories relevant here:

BPC-157 was added to the prohibited list in 2022. GLP-1 receptor agonists such as semaglutide and tirzepatide are not, as of this document's knowledge, on the prohibited list — but weight-class sports and individual federations may have their own rules, and the list changes yearly.

Verify every line of this table against the current Prohibited List at wada-ama.org before publishing. An out-of-date anti-doping table in a commercial product is a serious liability.

Additional bodies with their own lists: national anti-doping organisations, UFC/USADA-style promotion-specific programmes, the NCAA, professional league programmes, and the military drug policies of several countries. A "not on the WADA list" finding does not clear a substance under all of them.

Contraindications by mechanism class

Baseline panel

Nothing in this field is interpretable without a before. The excerpt tells the reader to "evaluate CRP and IL-6 at week 9" without ever establishing a baseline, which makes the week-9 number uninterpretable.

Metabolic: fasting glucose, fasting insulin (compute HOMA-IR), HbA1c, full lipid panel including ApoB, liver enzymes, renal function and eGFR.

Endocrine: IGF-1 (essential before anything touching the GH axis), TSH and free T4, total and free testosterone, SHBG, LH, FSH, oestradiol, prolactin, morning cortisol.

Inflammatory: hs-CRP. Note that IL-6 is not a standard clinical monitoring assay — it is short-lived, highly variable, rises acutely with exercise, and is not validated for tracking "chronic silent inflammation" in an individual. Building a protocol around serial IL-6 is measurement theatre.

Haematology and other: full blood count, ferritin, vitamin D, B12, folate, homocysteine.

Additional before incretins: lipase and amylase; calcitonin only if history warrants; thyroid and family history documented.

Additional for anyone over 40 or with risk factors: blood pressure, resting ECG, and age-appropriate cancer screening completed and current before any growth-factor exposure.

Monitoring cadence

Baseline, then week 6 to 8, then week 12, then quarterly. IGF-1 specifically on anything touching the GH axis, at every point. Fasting glucose and HbA1c on anything metabolic or GH-related.

Stop rules — seek medical assessment immediately

• Severe abdominal pain, particularly radiating to the back, with or without vomiting (pancreatitis)
• New persistent headache, visual change, or nausea on waking (intracranial pressure)
• Any new lump, mass, persistent lymph node, unexplained bleeding, or unexplained weight loss
• Any new, changing, bleeding or asymmetric mole
• Injection site: spreading redness, heat, swelling, fluctuance, or fever (abscess or cellulitis)
• New numbness, tingling, or hand weakness (carpal tunnel, common with GH axis)
• Chest pain, palpitations, syncope, or a sustained resting heart rate or blood pressure change
• Persistent vomiting, inability to keep fluids down, or signs of bowel obstruction on an incretin

Interactions

• GLP-1 and GIP/GLP-1 agonists delay gastric emptying, which alters the absorption of oral medicines. Narrow-therapeutic-index drugs need monitoring. Warfarin INR should be checked more frequently.
• Combining an incretin with insulin or a sulfonylurea requires reduction of the insulin or sulfonylurea dose, or hypoglycaemia results.
• GH affects cortisol metabolism via 11β-HSD1 and can unmask previously compensated adrenal insufficiency. It also affects thyroid hormone conversion, which can unmask hypothyroidism.
• Oral oestrogen reduces the IGF-1 response to GH, so requirements differ.
• Bremelanotide should not be combined with substances that raise blood pressure, given its transient pressor effect.

The sales page defers this entirely to a bonus. It is not a bonus. It is the difference between the molecule you think you have and the one in the vial.

What a certificate of analysis must contain

The trust chain

A vendor-supplied CoA is a vendor's claim. Independent third-party testing on the specific lot, commissioned by someone with no financial interest in the result, is evidence. Published analyses of grey-market peptide products have repeatedly found under-dosed vials, mislabelled compounds, and products containing something other than the labelled substance. Locate and cite specific published analyses before publishing this section — do not rely on the general claim.

Why the compounding route mattered

Before the FDA category 2 listing, a 503A compounding pharmacy in the US provided a route where the product was made under pharmacy standards, on a prescription, with a practitioner in the loop. The category 2 listing closed that route for the named substances, which pushed demand toward research-chemical supply, which has none of those controls. That is a real and under-discussed consequence of the regulatory action.

Included because dosing errors of a factor of ten are the most common serious harm in self-administration, and the arithmetic that prevents them is generic pharmacy maths.

The concentration calculation

Concentration equals total peptide mass divided by diluent volume.

A U-100 insulin syringe is graduated in units where 100 units = 1 mL, so 1 unit = 0.01 mL. This is the conversion where errors happen.

Worked example, purely as arithmetic:

Vial contains        : 5 mg peptide (net, after checking salt form)
Diluent added        : 2 mL bacteriostatic water
Concentration        : 5 mg / 2 mL = 2.5 mg/mL = 2500 mcg/mL
1 insulin unit       : 0.01 mL
Peptide per unit     : 2500 mcg/mL x 0.01 mL = 25 mcg per unit

Change the diluent volume and every subsequent number changes. Write the concentration on the vial in permanent marker at the moment of reconstitution.

Diluent choice

• Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, permitting repeated withdrawals from a multi-dose vial over a period of days.
• Sterile water for injection has no preservative and is single-use.
• Benzyl alcohol is contraindicated in neonates and in known hypersensitivity.

Technique

• Swab the vial stopper with alcohol and allow it to dry before every puncture.
• Add diluent slowly, directed down the inside wall of the vial, not straight onto the powder.
• Swirl gently. Do not shake. Peptides are shear-sensitive and agitation promotes aggregation, which both reduces potency and increases immunogenicity.
• Allow full dissolution. A solution that stays cloudy, discoloured, or shows particulates should be discarded, not used.
• New sterile needle for every draw and every injection. Sharps into a proper sharps container.

Storage

• Lyophilised powder: stable refrigerated or frozen, protected from light. Check the condition on arrival — a vial that arrived warm after several days in transit has an unknown history.
• After reconstitution: refrigerate at 2 to 8°C. Typical working guidance for many peptides in bacteriostatic water is a few weeks, but stability data for the research-only compounds is largely unpublished, and anyone stating a precise figure for BPC-157 or MOTS-c in solution is extrapolating.
• Do not freeze a reconstituted solution and do not freeze-thaw.
• Protect from light.

Route

Subcutaneous, intramuscular, intranasal and oral are not interchangeable. Route determines bioavailability, onset, and in some cases whether the compound reaches the target at all. Site rotation prevents lipohypertrophy and local reactions.

What this section does not cover

Combining two compounds in one vial or one syringe. Nothing in this document addresses physical co-mixing: whether two peptides are chemically compatible in solution, what a shared diluent does to the stability of either, whether one compound's counterion or pH affects the other, or how co-mixing changes adsorption to the vial and syringe surfaces. This is a real and commonly asked question and the honest answer here is that this reference cannot answer it.

Note that the practice is widespread and the silence is not endorsement. Compatibility is a formulation question with a compound-by-compound answer, and for the research-only compounds it is unlikely that anyone has generated the data at all — the stability figures for a single compound in bacteriostatic water are already largely unpublished, as noted above. See the verification queue, item 16.

Separately, and distinct from this: whether you should be running several compounds at once is a protocol-design question, not a handling one, and §14 principle 3 answers it.

Not prescriptions. The logic that separates a protocol from a ritual.

1. Frequency follows half-life. See §4. Any schedule that is not derived from the compound's own kinetics is arbitrary.
2. Pulsatile and continuous are different drugs. Especially on the GH axis. Continuous GPCR stimulation drives desensitisation.
3. Change one variable at a time. Stacking four compounds and reporting that "the protocol worked" produces no information. This is the single most common failure in the entire field, and it is what allows ineffective compounds to accumulate reputations.
4. Define the endpoint before you start, and make it measurable. "Better recovery" is not an endpoint. Grip strength, a specific lift at a specific RPE, hs-CRP, HOMA-IR, DEXA body composition, sleep-stage data, or a validated pain score are endpoints.
5. Baseline for long enough to see your own variance. Most biomarkers move substantially week to week for reasons unrelated to any intervention.
6. People start protocols at their worst. Regression to the mean will produce improvement in the absence of any effect. So will placebo, which is large for subjective endpoints like pain, energy and mood — precisely the endpoints this field markets on.
7. Minimum effective exposure, and a defined stop. Open-ended use of a compound with no long-term human safety data is an uncontrolled experiment with a sample size of one and no follow-up.
8. Washout and re-baseline before assessing anything new.
9. Time-to-signal differs by mechanism. Metabolic effects appear in weeks. Body composition takes months. Tissue repair is on the timescale of tissue repair, which no signalling molecule shortens below the biological floor.
10. Confirm the boring variables are fixed first. If sleep is 5 hours, protein intake is inadequate, alcohol is regular, or training is unprogrammed, no peptide is the limiting factor, and any effect will be swamped.

The excerpt's triad — insulin resistance, chronic inflammation, sleep dysregulation — is a reasonable organising frame. The mechanisms as written contain errors, and the intervention hierarchy is inverted.

Pillar 1 — insulin resistance

What the excerpt gets wrong. It states that a stress signal via CRH and cortisol "lowers blood glucose." Cortisol raises blood glucose, through hepatic gluconeogenesis and peripheral insulin antagonism. That is the entire point of the stress response. It also says "almost all glucose goes to fat tissue instead of muscle," which misstates the physiology: skeletal muscle is the site of roughly 70 to 80% of insulin-stimulated glucose disposal, and in insulin resistance muscle uptake falls while hepatic de novo lipogenesis rises.

What is actually established. Impaired GLUT4 translocation to the membrane, rather than simple receptor "downregulation," is the proximate defect in muscle. Critically, muscle contraction stimulates GLUT4 translocation through an insulin-independent, AMPK-linked pathway. This is why exercise improves glucose disposal in people whose insulin signalling is impaired, and it is the most robustly evidenced intervention available.

Measurement: fasting glucose with fasting insulin, computed as HOMA-IR; HbA1c; triglyceride-to-HDL ratio; ApoB; an oral glucose tolerance test with insulin if the picture is unclear.

Intervention hierarchy by evidence strength:

The excerpt's "molecular solutions" section presents rank 8 as the answer and does not mention ranks 1 through 4.

Pillar 2 — inflammation

What the excerpt gets wrong. It treats IL-6 as uniformly pathological. Skeletal muscle releases IL-6 during exercise as a myokine, and that exercise-induced IL-6 signal has net anti-inflammatory downstream effects, including induction of IL-10 and IL-1ra. Conflating exercise-derived IL-6 with adipose- and macrophage-derived chronic IL-6 is a substantive error, and it leads directly to the wrong conclusion, which is to suppress a signal that is part of the adaptation.

It also inverts LL-37, as noted in §8.

What is usable. hs-CRP is the practical marker, it is standardised, and it has outcome data behind it. "Chronic silent inflammation" is not a diagnosis and has no diagnostic criteria; it is a useful shorthand and should be labelled as one.

Established drivers of low-grade systemic inflammation: adiposity, particularly visceral; insufficient sleep; alcohol; smoking; periodontal disease; low dietary quality; physical inactivity; untreated sleep apnoea.

Intervention hierarchy: the same first four ranks as Pillar 1, plus treatment of periodontal disease and sleep apnoea where present. The peptide options in the excerpt's anti-inflammatory protocol — BPC-157, KPV, LL-37, SS-31 — are T4 for this purpose, and the one intervention in this space that received a properly powered human trial, larazotide for intestinal permeability, missed its endpoint.

The excerpt's "anti-inflammatory base protocol" — BPC-157 alone weeks 1-2, add SS-31 weeks 3-4, add MOTS-c weeks 5-8 — has no dose, no route, no frequency, and combines three compounds with no human efficacy data in a sequence that makes attribution impossible. It also violates its own principle of measurement by placing the first biomarker check at week 9, with no baseline.

Pillar 3 — sleep and the nocturnal axis

This is the pillar the excerpt truncates, and it is the one with the strongest human evidence. That inversion is the clearest single indicator of the document's priorities.

What is established in humans, with controlled designs:

• Growth hormone secretion is concentrated in the first episodes of slow-wave sleep. Fragmenting or suppressing slow-wave sleep suppresses the nocturnal GH pulse directly. No secretagogue restores a pulse the architecture is not there to support.
• Restricting healthy young men to approximately 4 hours in bed for 6 nights produced a marked reduction in glucose tolerance and insulin sensitivity (Spiegel, Leproult and Van Cauter, Lancet 1999). Verify the exact effect size before quoting a percentage.
• Restricting sleep to approximately 5 hours per night for one week reduced daytime testosterone by roughly 10 to 15% in healthy young men (Leproult and Van Cauter, JAMA 2011). Verify.
• Sleep restriction during caloric restriction shifted the composition of weight lost away from fat and toward lean mass (Nedeltcheva et al., Annals of Internal Medicine 2010). Verify.

The implication. These are randomised or crossover human studies with effect sizes larger than anything demonstrated for any unapproved peptide in this document, and the intervention is free. A product that positions itself as a performance system and truncates this section while leading with BPC-157 has its hierarchy exactly backwards.

Peptide angles, honestly stated: DSIP has essentially no human evidence of sleep induction. GHRH administration has been shown to modestly increase slow-wave sleep in research settings, which is mechanistically interesting and not a licensed use. Nothing here competes with sleep opportunity, timing regularity, light exposure, alcohol removal, and treatment of undiagnosed sleep apnoea.

Stated plainly, because a reference that hides its ignorance is worse than no reference.

• Long-term safety of every unapproved compound in this document is unknown. There are no multi-year human safety cohorts for BPC-157, TB-500, MOTS-c, epitalon, KPV, or the GHRPs.
• Cancer risk from chronic growth-factor and angiogenic signalling is unquantified. The mechanistic concern is real, the human data does not exist, and absence of data is not absence of risk.
• There is no human dose-response curve for most of these compounds. Where the market has settled on a number, that number's provenance is usually a forum, a vendor, or an allometric conversion from a rodent study.
• No human pharmacokinetics are published for BPC-157, TB-500 or MOTS-c, so even dosing frequency is guesswork.
• No pregnancy, breastfeeding or paediatric data for any unapproved compound.
• No systematic drug-interaction data.
• Effect sizes relative to baseline behaviour are unknown. Nobody has run a trial of a peptide against adequate sleep, and there is no reason to assume the peptide wins.
• Publication bias in the single-group corpora (Zagreb for BPC-157, St Petersburg for the bioregulators) is unquantified and structurally difficult to assess.
• Grey-market product identity and purity are unknown per-vial without independent lot testing, which almost nobody does.

AMPK

AMP-activated protein kinase; cellular energy sensor activated when ATP falls, and by exercise.

Bioavailability

fraction of an administered dose reaching systemic circulation unchanged.

Bioregulator

Khavinson's term for very short peptides proposed to act as regulatory signals on gene expression.

CoA

certificate of analysis; a document reporting the identity, purity and contaminant testing of a specific manufacturing lot.

DAC

drug affinity complex; a maleimide group that binds covalently to serum albumin, extending half-life dramatically.

Endotoxin

bacterial lipopolysaccharide; pyrogenic when injected. Measured by LAL assay in endotoxin units per mg.

GHRH

growth hormone-releasing hormone; acts on the pituitary, feedback intact.

GHRP

growth hormone-releasing peptide; ghrelin receptor agonist.

GLUT4

the insulin- and contraction-responsive glucose transporter in muscle and fat.

HOMA-IR

homeostatic model assessment of insulin resistance, computed from fasting glucose and fasting insulin.

hs-CRP

high-sensitivity C-reactive protein; the practical inflammation marker.

Lyophilised

freeze-dried; the stable powder form peptides ship in.

Myokine

a signalling molecule released by contracting skeletal muscle.

Net peptide content

the actual peptide mass in a vial after excluding counterion salt and water; usually below the labelled gross mass.

Pulsatile vs continuous

whether a receptor sees intermittent spikes or sustained elevation; determines desensitisation.

S0 / S2 / S4

WADA Prohibited List categories.

503A / 503B

US compounding pharmacy and outsourcing facility categories under the FD&C Act.

TFA

trifluoroacetic acid; common counterion from peptide synthesis and purification.

Nothing in this document should be published, sold, or relied on until these are checked against the named primary source. Items are ordered by consequence.

Written to fill the gaps identified in a teardown of the "Prime Peptides" product (emprendesinlimites.com/pep) and the module-1 excerpt supplied on 2026-09-03. The teardown found: no doses, no citations, no contraindications, no anti-doping content, no reconstitution or storage guidance, no baseline labs, and several factual errors, against a sales page promising exactly those things for $27.

This document is AI-synthesised and unverified. Treat every number in it as a hypothesis until §19 is cleared.